ROSE Diagnostics Secures $2.7M in Latest Funding Round to Advance verifi™ LUNG Test Toward FDA Approval

Carlsbad, CA – June 2026

ROSE Diagnostics Inc., a pioneer in rapid, point-of-care cancer diagnostics, today announced it has raised $2.7 million in its latest round of financing. The capital will be used to advance ROSE into the next stage of clinical development for the company's verifi™ LUNG Test, bringing them one step closer to getting their biopsy verification technology into clinics across the USA.

Structured as a private Regulation D offering, the round drew participation from both longtime backers and new investors, reflecting sustained confidence in the company's technology and commercial strategy.

With this funding in place, ROSE is set to launch its Pilot Clinical Study for the verifi™ LUNG Test in the near term, laying the groundwork for a pivotal study slated for 2027. Together, these studies represent the next major milestones on the company's roadmap toward FDA approval and eventual commercial launch.